Our researchers have found a way to dramatically slow neuroblastoma growth, using a combination of drugs that starves cells of essential nutrients called polyamines.
Groundbreaking research from our Leukaemia Biology Program has revealed how acute lymphoblastic leukaemia can become resistant to a class of anti-cancer drugs called glucocorticoids.
Our researchers have developed a method to measure the amount of copper inside neuroblastoma tumours. Published in the journal Theranostics, it offers a potential tool for treating and monitoring neuroblastoma.
A drug called OBI-3424 has been designated an Orphan Drug by the U.S. Food and Drug Administration (FDA) to treat acute lymphoblastic leukaemia, based predominantly on research carried out by our Leukaemia Biology Program.
September marks Children’s Cancer Awareness Month, a time to bring awareness of the devastating effects of childhood cancer and raise vital funds for research into finding a cure. To commemorate, Children’s Cancer Institute has engaged in a variety of awareness and fundraising activities throughout the month.
Research published this week shows that gold-coated nanoparticles can be used to detect tiny amounts of cancer-related molecules in blood.
NSW Health Minister Brad Hazzard has announced a $1 million funding boost for the Zero Childhood Cancer program. The money will support an immunotherapy trial for children with brain cancer.
Our scientists have found a way to rein in a cancer-causing gene called MYCN and slow down the growth of the childhood cancer neuroblastoma.
We’re thrilled to announce a new role at Children’s Cancer Institute – Research Team Leader. Applications are now open for emerging research leaders who’d like to establish their own independent cancer research careers.
It’s six months since the Zero Childhood Cancer personalised medicine national clinical trial began. We'd like to share some of our progress with you.